NOWS: Developmental Vulnerabilities Following Maternal Buprenorphine Exposure
I contributed to a literature review on neonatal opioid withdrawal syndrome (NOWS), focusing on developmental vulnerabilities following maternal buprenorphine exposure. Buprenorphine medications are FDA-approved for the treatment of opioid use disorder (OUD), and may be prescribed to pregnant women struggling with opioid addiction. There exists an inherent vulnerability in the offspring of mothers exposed to opioids during pregnancy that has not yet been systematically characterized with behavioral and biochemical outcomes. Thus, the objective of my research was to use the available literature to examine current models and existing knowledge on maternal buprenorphine exposure and NOWS. Preclinical rodent models provided varying insights and observations on the effects of maternal buprenorphine exposure on offspring.